Understanding Wilms Tumor Relapse Statistics

​

A relapse (also called a recurrence) occurs when Wilms tumor (nephroblastoma) returns after a child has completed treatment and was previously considered to have no evidence of disease or to be in remission. Although the majority of children diagnosed with Wilms tumor are successfully cured with modern treatment, a small proportion will experience a relapse, requiring additional investigation and treatment.

​

Understanding relapse statistics helps parents, caregivers, healthcare professionals, and researchers appreciate how often recurrence occurs, when it is most likely to happen, which children are at greatest risk, and how advances in pediatric oncology continue to improve outcomes after relapse. While relapse remains one of the greatest challenges in treating Wilms tumor, survival following recurrence has improved significantly through international collaboration, better risk stratification, and more effective treatment strategies.

​

How Common is Wilms Tumor Relapse?

​

The likelihood of relapse depends on several factors, including the stage of the tumour, histology, genetic characteristics, and the treatment initially received. Overall, approximately 15–20% of children diagnosed with Wilms tumor will experience a relapse following their first course of treatment. This means that around 80–85% of children remain free of recurrence after completing therapy.

​

Children with favourable histology generally have a much lower risk of relapse than those with diffuse anaplastic Wilms tumor, which is more resistant to treatment and associated with poorer outcomes.

​

Relapse Rates by Disease Stage

​

The risk of recurrence generally increases as the stage of Wilms tumor becomes more advanced. Although exact figures vary between international treatment protocols and individual studies, published data suggest the following approximate relapse rates for children treated in high-income countries (HICs).

Wilms Tumor StageApproximate Risk of Relapse (HICs)

​

• Stage I:  5 - 10%

• Stage II: 10 - 15%

• Stage III:15 - 20%

• Stage IV: 20 - 30%

• Stage V (Bilateral): 20 - 35%

 

Children with diffuse anaplastic histology or high-risk molecular features may experience substantially higher relapse rates than those shown above.

 

When Does Wilms Tumor Usually Relapse?

​

Most relapses occur relatively soon after treatment has finished.

​

Research has shown that:

​

• Approximately 80–90% of relapses occur within the first two years after completing treatment.

• The highest risk period is during the first 12–24 months.

• Relapse after five years is uncommon but can occasionally occur.

• Regular surveillance during the early years after treatment is therefore essential.

 

For this reason, children attend regular follow-up appointments involving physical examinations, imaging studies, blood tests, and other investigations designed to detect recurrence as early as possible.

 

Where Does Wilms Tumor Usually Return?

 

Wilms tumor can recur in several parts of the body. The most common sites include:

​

• Lungs (the most frequent site of relapse).

• Tumour bed within the abdomen.

• Remaining kidney (particularly in bilateral disease).

• Liver.

• Lymph nodes.

• Less commonly, bone, brain, or multiple sites simultaneously.

 

The location of the relapse influences treatment planning and overall prognosis.

 

Factors That Increase the Risk of Relapse

 

Not every child has the same risk of recurrence. Pediatric oncology teams carefully assess a number of clinical and biological factors when estimating relapse risk.

 

Important factors include:

​

• Higher tumour stage at diagnosis.

• Diffuse anaplastic histology.

• Certain genetic and molecular abnormalities, including 1q gain and loss of heterozygosity (LOH) at chromosomes 1p and 16q.

• Incomplete response to chemotherapy.

• Residual tumour following surgery.

• Metastatic disease at diagnosis.

• Bilateral (Stage V) Wilms tumor.

• Treatment modifications required because of toxicity or complications.

 

These factors help doctors classify children into different risk groups, allowing treatment to be tailored to maximise cure while minimising long-term side effects.

​

Relapse Statistics in High-Income Countries and LMICs

 

Children treated in high-income countries (HICs) generally experience lower relapse rates and better survival following recurrence because of access to specialist pediatric oncology centres, advanced diagnostic imaging, multidisciplinary care, intensive chemotherapy, surgery, radiation therapy, stem cell transplantation where appropriate, and comprehensive supportive care.

​

In many low- and middle-income countries (LMICs), relapse may be more common or more difficult to successfully treat because of factors such as:

​

• Delayed diagnosis.

• Limited access to specialist surgery.

• Restricted availability of chemotherapy or radiotherapy.

• Treatment abandonment.

• Limited surveillance imaging after treatment.

• Delays in recognising recurrent disease.

• Reduced access to salvage therapies.

 

As healthcare systems strengthen and international partnerships expand, outcomes following relapse continue to improve in many LMICs.

 

Survival After Relapse

​

Although relapse is a serious event, it is not the end of the treatment journey. Many children who experience recurrent Wilms tumor can still be successfully treated. Approximate outcomes reported in modern treatment programmes include:

​

• Favourable histology, first relapse; 50–70%

• Late relapse (>12 months); 60–80%

• Diffuse anaplastic histology; 20–40%

• Early relapse (<6 months)

• Lower survival than late relapse

 

The exact outlook depends on factors including where the tumour returns, how quickly it relapses, previous treatment received, tumour biology, and the child's response to salvage therapy.

 

Why Relapse Outcomes Continue to Improve

 

Over the past several decades, international research has significantly improved the treatment of recurrent Wilms tumor. Organisations such as the Children's Oncology Group (COG), the International Society of Paediatric Oncology (SIOP), the National Wilms Tumor Study (NWTS), and the SIOP-RTSG UMBRELLA programme continue to refine treatment strategies through clinical trials and collaborative research.

​

Important advances include:

​

• Improved risk stratification.

• Better molecular profiling.

• More effective chemotherapy combinations.

• Advances in surgery and radiation therapy.

• High-dose chemotherapy and stem cell transplantation for selected patients.

• Improved supportive care.

• Earlier detection through structured surveillance programmes.

 

These advances continue to improve survival while reducing treatment-related complications.

 

Understanding Relapse Statistics

 

Relapse statistics provide valuable information about large groups of children but cannot predict what will happen to an individual child. Every child's diagnosis is different, and many factors influence whether a tumour returns and how well it responds to further treatment.

​

For families, relapse statistics should be viewed as a guide to understanding the disease rather than a prediction of the future. The best source of information about your child's individual prognosis will always be your pediatric oncology team, who can explain how factors such as tumour stage, histology, genetic findings, response to treatment, and overall health influence your child's outlook.

​

Key Facts at a Glance

​

• Children experiencing relapse15–20%

• Children remaining relapse-free after treatment80–85%

• Relapses occurring within two years80–90%

• Most common site of relapseLungs

• Stage I relapse risk5–10%

• Stage IV relapse risk20–30%

• Survival after first favourable histology relapse50–70%